1774. Ridinilazole (RDZ) for Clostridium difficile infection (CDI): Correlation of In Vitro Spectrum of Activity with Human Gut Microbiome Profiles from a Phase 2 Clinical Trial

BACKGROUND: Recurrence of CDI (rCDI) is associated with perturbation of the gut microbiome during treatment with vancomycin (VAN) or metronidazole (MTZ). RDZ is a novel, targeted spectrum antibacterial under investigation to treat CDI and reduce rCDI. Here correlation of in vitro spectrum of activit...

Descripción completa

Detalles Bibliográficos
Autores principales: Vickers, Richard, Goldstein, Ellie J C, Citron, Diane, Snydman, David, Thorpe, Cheleste M, Kane, Anne V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252795/
http://dx.doi.org/10.1093/ofid/ofy209.159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252795/
http://dx.doi.org/10.1093/ofid/ofy209.159

Ejemplares similares